Commentary on Pardo et al. (2020): Addressing fentanyl-related harms: maximising the efficiency of innovative interventions.

Dr Tom May*
Research Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, University College London, 1-19 Torrington Place, London, WC1E 7HB.
t.may@ucl.ac.uk

Dr Marian Buhociu
Substance Use Research Group (SURG), Centre for Criminology, University of South Wales, Pontypridd, CF37 1DL.

Professor Katy Holloway
Substance Use Research Group (SURG), Centre for Criminology, University of South Wales, Pontypridd, CF37 1DL.

*corresponding author

Word Count: 746

Conflict of Interest: None

Declaration of Interest: None
Abstract:

As fentanyl expands into new markets, innovative interventions are needed to reduce further harms. In this context, public health responses that combine the knowledge and expertise of people who use drugs with interventions attending to the social-structural production of fentanyl-related harm should be pursued.
Pardo and colleagues highlight the need for innovative interventions in a ‘new synthetic opioid era’ (1). This is a timely and welcome piece given the increase in fatal opioid overdoses linked to fentanyl and analogues in North America and the ‘emerging’ threat they pose to people who use drugs (PWUD) in the UK (2). In this paper, we expand on this debate and discuss two further options that might assist with the innovation and development of future interventions.

Although we recognise a need to act with urgency to prevent further harm, we also underline the importance of combining policy or technological innovations with the knowledge and expertise of PWUD themselves (3, 4). Indeed, as fentanyl expands into and becomes a feature of new drug markets (5), it is important to consider how this is likely to shape the responses of PWUD to its presence, and impact on their acceptability and use of interventions designed to reduce harm. In communities where fentanyl-adulterated heroin is endemic there is evidence that some PWUD are accepting of fentanyl through lack of alternatives, and in some cases have even developed a preference for it (4, 6). Whilst testing and public health messaging may therefore have utility at a stage where individuals are concerned about fentanyl exposure, they are unlikely to discourage PWUD if traditional opioids have become displaced from the market, or deter those who are actively seeking fentanyl (3, 7). Our point here is not that these existing measures have little value, but rather, to illustrate the importance of understanding the situated and pragmatic responses of PWUD to fentanyl and associated interventions (3). In this context, we suggest any innovation or development of future measures should be considered alongside the lived contexts of fentanyl use if they are to be acceptable and ultimately effective (3).

We agree with Pardo and colleagues that ‘innovation can begin at the margins’ and consider this a useful setting for the invention of novel approaches. There is evidence that some PWUD initiate their own protective strategies in response to fentanyl or adulterated-heroin, including switching from injecting to smoking, incremental dosing, or seeking to identify the presence of fentanyl through visual appearance or taste (3, 4, 8). Understanding these ‘indigenous responses’ can enable the insertion of pragmatic solutions into future interventions that attend to the immediate needs and priorities of some PWUD (8). Many harm reduction programmes evolved out of peer-led efforts in response to the HIV epidemic of the 1980s and are now evidenced public health interventions (e.g. needle syringe programmes) (3). The emergence of fentanyl provides a similar context where we can harness the expertise of PWUD to develop innovative and effective responses.
Secondly, it is reasonable to assume that pre-existing social-structural factors will continue to limit the risk-reducing capacities of future interventions, regardless of any innovation. Whilst fentanyl-related deaths in North America are elevated in socio-economically disadvantaged regions (9) and urban areas with large homeless and street-injecting scenes (10), substantial increases have recently occurred among demographics with traditionally lower levels of opioid use, including women (11) and those from rural communities (12). Regardless of location, these are populations disproportionately impacted by social, political and economic systems of disadvantage (e.g. stigma, gendered inequities, homelessness, socio-economic deprivation), all of which shape susceptibility to drug-related harms (13).

Recognising this, future interventions might benefit from orientating toward an approach that responds to these multiple vulnerabilities. This would involve moving beyond individual-level approaches seeking to modify behaviour to one attuned to the environment(s) – whether social, political, economic or physical – in which harms occur (13). Previous work has documented how Safe Injecting Facilities (SIFs) and low-threshold, integrated services (‘one-stop-shop’ models) - whereby multiple services addressing complex health and social care issues are co-located within one facility – can mediate the contextual factors producing drug-related harms (e.g. poverty, housing instability, gendered risk) through the provision of broader environmental and social support (14-16). This includes facilitating access to medical care, food and shelter and social welfare support (14, 15). Whilst such interventions can lead to the creation of enabling environments that align with the diverse and intersecting needs of affected populations, we recognise that their implementation often involves difficulty. Here, community and drug-user activism have been instrumental in altering legal and bureaucratic processes opposed to the operation of SIFs, for example, (17), and similar advocacy can be effective in establishing innovative interventions in locations where social, legal and political barriers limit implementation (18). Pursuing broader social-structural reforms might be challenging, but, in tandem with the inclusion of PWUD in key policy and public health dialogues, can lead to opportunities for the creation of truly innovative interventions in the synthetic opioid era (4, 19).


